Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00400309 | Safety of REPEVAX® Given One Month After REVAXIS® | PHASE3 | COMPLETED | 500 | — | — | Jun 1, 2006 | Feb 1, 2007 | Sep 11, 2017 | 4 | France |
| Arm | Type | Description |
|---|---|---|
| REPEVAX® after REVAXIS® | EXPERIMENTAL | REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28). |
| REPEVAX® after Placebo | ACTIVE_COMPARATOR | Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28). |
| Name | Type | Description |
|---|---|---|
| REPEVAX® after REVAXIS® | BIOLOGICAL | Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated) |
| REPEVAX® after Placebo | BIOLOGICAL | Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo |
Inclusion Criteria: * Healthy adult, with vaccination history (by written evidence) of a minimum of 5 doses of a tetanus, diphtheria and poliomyelitis containing vaccine as recommended in the French vaccination calendar at 18 years old, and a maximum of 8 doses. * Last dose of a tetanus and/or diph...